Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Author’s View
  • Published:

Antibodies target intracellular oncodrivers through PIGR-mediated transcytosis

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Antigen-specific dIgA and intracellular target interact in early and late endosomes inside tumor cells.


  1. Mazanec MB, Kaetzel CS, Lamm ME, Fletcher D, Nedrud JG. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci USA. 1992;89:6901–5.

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

  2. Biswas S, Mandal G, Payne KK, Anadon CM, Gatenbee CD, Chaurio RA, et al. IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature. 2021;591:464–70.

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

  3. Mandal G, Biswas S, Anadon CM, Yu X, Gatenbee CD, Prabhakaran S, et al. IgA-dominated humoral immune responses govern patients’ outcome in endometrial cancer. Cancer Res. 2022;82:859–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Biswas S, Mandal G, Anadon CM, Chaurio RA, Lopez-Bailon LU, Nagy MZ, et al. Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers. Immunity. 2023;56:2570–83.e6.

    Article  CAS  PubMed  Google Scholar 

  5. Xue JY, Zhao Y, Aronowitz J, Mai TT, Vides A, Qeriqi B, et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature. 2020;577:421–5.

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

Download references


This study was supported by the National Institutes of Health R01CA157664, R01CA124515, R01CA178687, and R01CA278907 to JRCG.

Author information

Authors and Affiliations



The 3 authors worked on developing the text, based on a consensus on the interpretation of existing results and future refinements of this technology. JRCG elaborated the Figure.

Corresponding author

Correspondence to Jose R. Conejo-Garcia.

Ethics declarations

Competing interests

JRCG has stock options in Compass Therapeutics, Anixa Biosciences and Alloy Therapeutics; has sponsored research with Anixa Biosciences; receives an honorarium from Alloy Therapeutics; and intellectual property with Compass Therapeutics and Anixa Biosciences; and is co-founder of Cellepus Therapeutics; all outside the submitted work. JRCG, SB and CMA have filed a patent application for intracellular targeting of oncodrivers using modified IgG.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Biswas, S., Anadon, C.M. & Conejo-Garcia, J.R. Antibodies target intracellular oncodrivers through PIGR-mediated transcytosis. Genes Immun 25, 85–86 (2024).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links